Company Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer.
The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial.
It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.
Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Douglas Onsi |
Contact Details
Address: 47 Thorndike Street, Suite B1-1 Cambridge, Massachusetts 02141 United States | |
| Phone | 617 714 0360 |
| Website | leaptx.com |
Stock Details
| Ticker Symbol | LPTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001509745 |
| CUSIP Number | 52187K101 |
| ISIN Number | US52187K2006 |
| Employer ID | 27-4412575 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas E. Onsi J.D. | Chief Financial Officer, General Counsel, Treasurer and Secretary, President, Chief Executive Officer & Director |
| Augustine J. Lawlor | Chief Operating Officer |
| Dr. Cynthia A. Sirard M.D. | Chief Medical Officer |
| Dr. Jason S. Baum Ph.D. | Chief Scientific Officer |
| Mark O'Mahony | Chief Manufacturing Officer |
| Christine M. Granfield | Vice President and Head of Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | 8-K | Current Report |
| May 13, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 8-K | Current Report |